RayKnowChina Research Map
Shortlist0

ShanghaiNaval Medical University

Eastern Hepatobiliary Surgery Hospital

海军军医大学第三附属医院(东方肝胆外科医院)

Listed for 6 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Eastern Hepatobiliary Surgery Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌214 papers led4 open trials led
  2. Stomach cancer胃癌6 papers led
  3. Osteosarcoma骨肉瘤4 papers led
  4. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  5. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  6. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 214 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.5%.

Papers led
214
2021–2025
Trials led
55
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 444420212022: 484820222023: 414120232024: 404020242025: 37372025

15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06902389

    Age 18 years to 75 years (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  2. Recruiting
    The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
    Phase
    Phase 2/Phase 3
    Started
    2025-10
    Registry
    NCT07285850

    Age 18 years to Not stated (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  3. Not yet recruiting
    A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07337031

    Age 18 years to 75 years (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  4. Not yet recruiting
    Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07363356

    Age 18 years to 70 years (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  5. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

  6. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  7. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

  8. Enrolling by invitation
    Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06712017

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisSurgery & liver transplantImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicineMedical oncology
Papers it led214
  1. LGR5/mTORC2 axis regulates cellular metabolic plasticity to maintain tumorigenesis in hepatocellular carcinoma.2026Cancer letters
  2. Novel dual-targeted modified polyester albumin nano-carriers enhance the efficacy of hepatocellular carcinoma outcomes after encapsulating lenvatinib.2026Journal of biomaterials applications
  3. RAC1 directly phosphorylates both PKM2 and FBP1 to promote radioresistance in hepatocellular carcinoma.2026Molecular therapy : the journal of the American Society of Gene Therapy
  4. Deciphering the significance of tumor necrosis and developing a grading system in combined hepatocellular-cholangiocarcinoma: A multicenter pathological study.2026Pathology, research and practice
  5. Next-Generation Flexible Embolic Systems: Targeted Transarterial Chemoembolization Strategies for Hepatocellular Carcinoma.2025Advanced materials (Deerfield Beach, Fla.)
  6. Hydrogen-Bonded Organic Framework Nanoscintillators for X-Ray-Induced Photodynamic Therapy in Hepatocellular Carcinoma.2025Advanced materials (Deerfield Beach, Fla.)
  7. Cost-Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  8. Development models to predict complication and prognosis following liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension.2025American journal of surgery
  9. Development and Validation of an Individualized Prediction Model for Postoperative Late Recurrence After Hepatectomy for Hepatocellular Carcinoma (POLAR-HCC): A Multicenter Study.2025Annals of surgical oncology
  10. Statistical Cure After Hepatectomy for Hepatitis B Virus-Associated Hepatocellular Carcinoma: A Risk-Stratification Model.2025Annals of surgical oncology
  11. α-Fetoprotein model versus Milan criteria in predicting outcomes after hepatic resection for hepatocellular carcinoma: multicentre study.2025BJS openFree full text
  12. The role of prognostic nutrition index in the prognosis of patients with advanced hepatocellular carcinoma who received first-line therapy.2025BMC cancerFree full text
  13. Radiofrequency ablation versus stereotactic body radiotherapy for recurrent hepatocellular carcinoma: a multicenter, propensity score matching analysis.2025BMC cancerFree full text
  14. Integrated ultrasound radiomics and clinical data to predict PD-1 blockade efficacy in unresectable hepatocellular carcinoma.2025BMC gastroenterologyFree full text
  15. Repeat laparoscopic hepatectomy versus radiofrequency ablation for recurrent hepatocellular carcinoma: A multicenter, propensity score matching analysis.2025Bioscience trends
  16. Risk stratification model for predicting distant metastasis after hepatectomy for hepatocellular carcinoma: A multi-institutional analysis.2025Bioscience trends
  17. Intranuclear paraspeckle-circular RNA TACC3 assembly forms RNA-DNA hybrids to facilitate MASH-related hepatocellular carcinoma growth in an m6A-dependent manner.2025Cancer communications (London, England)Free full text
  18. Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  19. Drug resistance in TKI therapy for hepatocellular carcinoma: Mechanisms and strategies.2025Cancer letters
  20. Comparison of clinical characteristics and outcomes in patients with hepatocellular carcinoma based on serum alpha-fetoprotein status.2025European journal of gastroenterology & hepatology
  21. CCDC137/DGCR8 axis promotes aerobic glycolysis in hepatocellular carcinoma via activation of the AKT/mTOR signaling pathway.2025European journal of medical researchFree full text
  22. Prediction models after hepatectomy for hepatocellular carcinoma-based ultrasonic radiomics: an observational study.2025European journal of medical researchFree full text
  23. Trajectories of postoperative hepatitis B virus (HBV) DNA and HBV-related hepatocellular carcinoma outcomes.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  24. Heterogeneity in prognosis for early-stage hepatocellular carcinoma after hepatectomy: A multicenter analysis of 4,623 patients across five major staging systems.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  25. Preoperative ASAP score predicts recurrence and survival following curative hepatic resection for hepatitis B virus-related hepatocellular carcinoma: A multicenter cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  26. Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: A ten-year retrospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  27. Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  28. Impact of compliance to postoperative regular follow-up on long-term prognosis after curative resection for hepatocellular carcinoma: A multicenter analysis.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  29. HBcrAg is associated with prognosis of hepatitis B virus-related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy.2025International journal of cancer
  30. Perineural invasion as a prognostic determinant in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  31. Tumor biology characteristics score based on alpha-fetoprotein and protein induced by vitamin K absence or antagonist II as a predictor for recurrence and survival after curative resection for hepatocellular carcinoma: a multicenter cohort 2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  32. Liver ischemia-reperfusion promotes tumor metastasis via neutrophil-endothelial interactions: targeting ICAM1 to prevent metastatic recurrence.2025Journal of translational medicineFree full text
  33. microRNA-2117 Negatively Regulates Liver Cancer Stem Cells Expansion and Chemoresistance Via Targeting SOX2.2025Molecular carcinogenesisFree full text
  34. [Expression of Concern] Inhibition of tumorigenesis and invasion of hepatocellular carcinoma by siRNA‑mediated silencing of the livin gene.2025Molecular medicine reportsFree full text
  35. CYB5D2 inhibits the malignant progression of hepatocellular carcinoma by inhibiting TGF-β expression and epithelial-mesenchymal transition.2025Oncology researchFree full text
  36. Effect of Early Tumor Shrinkage and Depth of Response on the Clinical Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization and Lenvatinib plus PD-1 Inhibitors.2025Oncology research and treatment
  37. Ultrasounic-radiomics models for predicting the response to Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma.2025PloS oneFree full text
  38. Stereotactic body radiotherapy versus laparoscopic liver resection for single hepatocellular carcinoma ≤ 5 cm: a retrospective, multicenter, cohort study.2025Scientific reportsFree full text
  39. Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial.2025Signal transduction and targeted therapyFree full text
  40. Attenuation trend of alpha-fetoprotein predicts postoperative prognosis in alpha-fetoprotein-positive hepatocellular carcinoma patients.2025Surgery
  41. Postoperative adjuvant transarterial chemoembolization prolongs overall survival in alpha-fetoprotein-negative hepatocellular carcinoma with bile duct tumor thrombosis: a long-term retrospective cohort study.2025World journal of surgical oncologyFree full text
  42. Preoperative evaluation of MRI features and inflammatory biomarkers in predicting microvascular invasion of combined hepatocellular cholangiocarcinoma.2024Abdominal radiology (New York)Free full text
  43. Optimizing predictions: improved performance of preoperative gadobenate-enhanced MRI hepatobiliary phase features in predicting vessels encapsulating tumor clusters in hepatocellular carcinoma-a multicenter study.2024Abdominal radiology (New York)
  44. Preoperative Three-Dimensional Morphological Tumor Features Predict Microvascular Invasion in Hepatocellular Carcinoma.2024Academic radiology
  45. Hydrogel Crosslinked with Nanoparticles for Prevention of Surgical Hemorrhage and Recurrence of Hepatocellular Carcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  46. Development and validation of prealbumin-bilirubin score (preALBI score) for predicting long-term survival after hepatectomy for hepatocellular carcinoma: A multicenter analysis versus ALBI score.2024American journal of surgery
  47. Association of preoperative frailty with short- and long-term outcomes after hepatic resection for elderly patients with hepatocellular carcinoma: multicentre analysis.2024BJS openFree full text
  48. F13B regulates angiogenesis and tumor progression in hepatocellular carcinoma via the HIF-1α/VEGF pathway.2024Biomolecules & biomedicineFree full text
  49. Transcription factor ASCL1 targets SLC6A13 to inhibit the progression of hepatocellular carcinoma via the glycine-inflammasome signaling.2024Biomolecules & biomedicineFree full text
  50. METTL3-Mediated m6A Modification of FMRP Drives Hepatocellular Carcinoma Progression and Indicates Poor Prognosis.2024Cancer biotherapy & radiopharmaceuticals
  51. Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma.2024Cancer immunology, immunotherapy : CIIFree full text
  52. Spatial multimodal analysis revealed tertiary lymphoid structures as a risk stratification indicator in combined hepatocellular-cholangiocarcinoma.2024Cancer letters
  53. Identification of SPP1+ macrophages in promoting cancer stemness via vitronectin and CCL15 signals crosstalk in liver cancer.2024Cancer letters
  54. Expression Characteristics, Immune Signature, and Prognostic Value of the SOCS Family Identified by Multiomics Integrative Analysis in Liver Cancer.2024Cancer reports (Hoboken, N.J.)Free full text
  55. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities.2024Cancer scienceFree full text
  56. miR-4461 inhibits liver cancer stem cells expansion and chemoresistance via regulating SIRT1.2024Carcinogenesis
  57. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.2024Cell death & diseaseFree full text
  58. Baicalein Targets MAPK9 to Induce Apoptosis of Hepatocellular Carcinoma Cells.2024Chemical biology & drug design
  59. Cell-free DNA testing for early hepatocellular carcinoma surveillance.2024EBioMedicineFree full text
  60. Early prediction of microvascular invasion (MVI) occurrence in hepatocellular carcinoma (HCC) by 18F-FDG PET/CT and laboratory data.2024European journal of medical researchFree full text
  61. Spatial multiomics reveals a subpopulation of fibroblasts associated with cancer stemness in human hepatocellular carcinoma.2024Genome medicineFree full text
  62. Nuclear translocation of plasma membrane protein ADCY7 potentiates T cell-mediated antitumour immunity in HCC.2024GutFree full text
  63. B. thetaiotaomicron-derived acetic acid modulate immune microenvironment and tumor growth in hepatocellular carcinoma.2024Gut microbesFree full text
  64. Preoperative frailty as a key predictor of short- and long-term outcomes among octogenarians undergoing hepatectomy for hepatocellular carcinoma: a multicenter comprehensive analysis.2024HPB : the official journal of the International Hepato Pancreato Biliary Association
  65. A new scoring system for predicting the outcome of hepatocellular carcinoma patients without microvascular invasion-a large-scale multicentre study.2024HPB : the official journal of the International Hepato Pancreato Biliary Association
  66. Collagen in hepatocellular carcinoma: A novel biomarker and therapeutic target.2024Hepatology communicationsFree full text
  67. Association of diabetes mellitus with long-term prognosis after ablation therapy for patients with hepatocellular carcinoma: A single-center cohort study.2024Journal of cancer research and therapeutics
  68. Efficacy of microwave ablation with parallel acupuncture guided by ultrasound in treating single hepatocellular carcinoma in high-risk areas: A retrospective analysis of 155 patients.2024Journal of cancer research and therapeutics
  69. A new chemotherapy strategy for advanced hepatocellular carcinoma with exrahepatic metastasis: predictors of long-term survival.2024Journal of chemotherapy (Florence, Italy)
  70. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.2024MedicineFree full text
  71. Deep whole-genome analysis of 494 hepatocellular carcinomas.2024Nature
  72. Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial.2024Nature communicationsFree full text
  73. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.2024Nature medicineRCT
  74. Clinical significance of small nuclear ribonucleoprotein U1 subunit 70 in patients with hepatocellular carcinoma.2024PeerJFree full text
  75. lncRNA POLR2J4 Plays a Biomarker Role in Hepatitis B Virus-Related Hepatocellular Carcinoma Through Regulating miR-214-3p.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  76. Interleukin-17A educated hepatic stellate cells promote hepatocellular carcinoma occurrence through fibroblast activation protein expression.2024The journal of gene medicine
  77. Prognostic significance of postoperative serological incomplete conversion of AFP and PIVKA-II after hepatic resection for hepatocellular carcinoma: a multicenter analysis of 1755 patients.2024The oncologistFree full text
  78. Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody.2024The oncologistFree full text
  79. Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study.2024The oncologistFree full text
  80. Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma.2024TheranosticsFree full text
  81. Predicting hepatocellular carcinoma: A new non-invasive model based on shear wave elastography.2024World journal of gastroenterologyFree full text
  82. TWEAK Signaling-Induced ID1 Expression Drives Malignant Transformation of Hepatic Progenitor Cells During Hepatocarcinogenesis.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  83. Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis.2023Annals of hepatology
  84. ASO Author Reflections: Effect of Preoperative Metabolic Syndrome for Patients with Hepatocellular Carcinoma.2023Annals of surgical oncology
  85. Association of Concurrent Metabolic Syndrome with Long-term Oncological Prognosis Following Liver Resection for Hepatocellular Carcinoma Among Patients with Chronic Hepatitis B Virus Infection: A Multicenter Study of 1753 Patients.2023Annals of surgical oncology
  86. A nomogram for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma based on spleen-volume-to-platelet ratio.2023Asian journal of surgery
  87. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.2023BMC cancerFree full text
  88. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.2023Briefings in bioinformaticsFree full text
  89. Serologic status and safety of inactivated Covid-19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection.2023Cancer communications (London, England)Free full text
  90. Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study.2023Cancer medicineFree full text
  91. A reasonable identification of the early recurrence time based on microvascular invasion for hepatocellular carcinoma after R0 resection: A multicenter retrospective study.2023Cancer medicineFree full text
  92. Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment.2023Cellular & molecular immunologyFree full text
  93. Phosphotriesterase-related protein as a novel prognostic predictor for hepatocellular carcinoma patients.2023Chinese clinical oncology
  94. Cidan Capsule in Combination with Adjuvant Transarterial Chemoembolization Reduces Recurrence Rate after Curative Resection of Hepatocellular Carcinoma: A Multicenter, Randomized Controlled Trial.2023Chinese journal of integrative medicineRCT
  95. Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences.2023Clinical and molecular hepatologyFree full text
  96. Discovering the digital biomarker of hepatocellular carcinoma in serum with SERS-based biosensors and intelligence vision.2023Colloids and surfaces. B, Biointerfaces
  97. Prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma based on preoperative contrast-enhanced CT and clinical data.2023European journal of radiology
  98. Circular RNA cFAM210A, degradable by HBx, inhibits HCC tumorigenesis by suppressing YBX1 transactivation.2023Experimental & molecular medicineFree full text
  99. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.2023Frontiers in immunologyFree full text
  100. Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  101. Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.2023Frontiers in immunologyFree full text
  102. Hypoxia-induced circRTN4IP1 promotes progression and glycolysis of hepatocellular carcinoma cells.2023Functional & integrative genomics
  103. Prospective validation of the Eastern Staging in predicting survival after surgical resection for patients with hepatocellular carcinoma: a multicenter study from China.2023HPB : the official journal of the International Hepato Pancreato Biliary Association
  104. Development of preoperative prognostic models including radiological features for survival of singular nodular HCC patients.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  105. Laparoscopic and open liver resection for hepatocellular carcinoma with type 2 diabetes mellitus: multicenter propensity score-matched study.2023Hepatology international
  106. Structural changes and anti-hepatocellular carcinoma activity of interferon-γ after interaction with sinensetin.2023International journal of biological macromolecules
  107. N6-Methyladenosine Modification of ANLN Enhances Hepatocellular Carcinoma Bone Metastasis.2023International journal of biological sciencesFree full text
  108. Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection.2023JAMA network openFree full text
  109. Mechanisms of portal vein tumour thrombus formation and development in patients with hepatocellular carcinoma.2023Journal of cellular and molecular medicineFree full text
  110. The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis.2023Journal of hematology & oncologyFree full text
  111. Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells.2023Journal of hepatology
  112. Orthogonally Engineered Albumin with Attenuated Macrophage Phagocytosis for the Targeted Visualization and Phototherapy of Liver Cancer.2023Journal of the American Chemical Society
  113. A new and rare type of hepatocellular carcinoma: Survival and gene analysis of portal vein tumour thrombus-type hepatocellular carcinoma.2023Pathology, research and practice
  114. High-throughput sequencing approach for the identification of lncRNA biomarkers in hepatocellular carcinoma and revealing the effect of ZFAS1/miR-150-5p on hepatocellular carcinoma progression.2023PeerJFree full text
  115. Immune index: A gene and cell prognostic signature for immunotherapy response prediction in hepatocellular carcinoma.2023Pharmacological research
  116. Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.2023Signal transduction and targeted therapyRCTFree full text
  117. Preoperative and Prognostic Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Review Based on Artificial Intelligence.2023Technology in cancer research & treatmentFree full text
  118. Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE.2023Technology in cancer research & treatmentFree full text
  119. GPNMB+ Gal-3+ hepatic parenchymal cells promote immunosuppression and hepatocellular carcinogenesis.2023The EMBO journalFree full text
  120. The Comparison of Surgical Margins and Type of Hepatic Resection for Hepatocellular Carcinoma With Microvascular Invasion.2023The oncologistFree full text
  121. Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE.2023The oncologistFree full text
  122. Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma.2023World journal of surgical oncologyFree full text
  123. Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells.2022Acta pharmacologica SinicaFree full text
  124. Post-hepatectomy liver failure prediction and prevention: Development of a nomogram containing postoperative anticoagulants as a risk factor.2022Annals of hepatology
  125. Evaluation of nuclear PGAM2 value in hepatocellular carcinoma prognosis.2022Anti-cancer drugsFree full text
  126. Long-term oncological prognosis after curative-intent liver resection for hepatocellular carcinoma in the young versus the elderly: multicentre propensity score-matching study.2022BJS openFree full text
  127. Laparoscopic right hemihepatectomy following a novel optimized portal vein embolization: a video case report.2022BMC gastroenterologyFree full text
  128. Preoperative diagnosis and prediction of microvascular invasion in hepatocellularcarcinoma by ultrasound elastography.2022BMC medical imagingFree full text
  129. Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol.2022BMJ openFree full text
  130. DANCR deletion retards the initiation and progression of hepatocellular carcinoma based on gene knockout and patient-derived xenograft in situ hepatoma mice model.2022Cancer letters
  131. Gankyrin and TIGAR cooperatively accelerate glucose metabolism toward the PPP and TCA cycle in hepatocellular carcinoma.2022Cancer scienceFree full text
  132. DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334.2022Cell death & diseaseFree full text
  133. Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis.2022Cell death & diseaseFree full text
  134. A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study.2022Chinese medical journalFree full text
  135. Novel transketolase inhibitor oroxylin A suppresses the non-oxidative pentose phosphate pathway and hepatocellular carcinoma tumour growth in mice and patient-derived organoids.2022Clinical and translational medicineFree full text
  136. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.2022Clinics and research in hepatology and gastroenterology
  137. Response to letter entitled: Re: 'Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial'.2022European journal of cancer (Oxford, England : 1990)
  138. Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial.2022European journal of cancer (Oxford, England : 1990)RCT
  139. A novel classification in predicting prognosis and guiding postoperative management after R0 liver resection for patients with hepatocellular carcinoma and microvascular invasion.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  140. Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: A multicenter propensity score matc2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  141. Association of type 2 diabetes mellitus with incidences of microvascular invasion and survival outcomes in hepatitis B virus-related hepatocellular carcinoma after liver resection: A multicenter study.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  142. Reply to: Letter to the Editor "Association of type 2 diabetes mellitus with incidences of microvascular invasion and survival outcomes in hepatitis B virus-related hepatocellular carcinoma after liver resection: A multicenter study".2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  143. Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial.2022Future oncology (London, England)
  144. Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China.2022HPB : the official journal of the International Hepato Pancreato Biliary Association
  145. Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis.2022HPB : the official journal of the International Hepato Pancreato Biliary Association
  146. Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study.2022HPB : the official journal of the International Hepato Pancreato Biliary Association
  147. A stable and reliable animal model for hepatocellular carcinoma with portal vein tumor thrombus.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  148. Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial.2022Hepatology internationalRCT
  149. Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.2022Hepatology internationalFree full text
  150. A deep learning model with incorporation of microvascular invasion area as a factor in predicting prognosis of hepatocellular carcinoma after R0 hepatectomy.2022Hepatology international
  151. Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages 0-A hepatocellular carcinoma patients associated with or without microvascular invasion: a multicenter, propensity score matching a2022Hepatology international
  152. Image-matching digital macro-slide-a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma.2022Hepatology internationalFree full text
  153. Association of Adjuvant Radiation Therapy With Long-Term Overall and Recurrence-Free Survival After Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-Matched Study.2022International journal of radiation oncology, biology, physics
  154. Development and validation of safety and efficacy-associated risk calculator for hepatocellular carcinoma in the elderly after resection (SEARCHER): A multi-institutional observational study.2022International journal of surgery (London, England)
  155. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.2022International journal of surgery (London, England)
  156. Comparison of percutaneous microwave ablation with radiofrequency ablation for hepatocellular carcinoma adjacent to major vessels: A retrospective study.2022Journal of cancer research and therapeutics
  157. Immune-related lncRNA signature delineates an immune-excluded subtype of liver cancer with unfavorable clinical outcomes.2022Journal of clinical laboratory analysisFree full text
  158. Metabolome and transcriptome integration reveals metabolic profile of hepatocellular carcinoma.2022Journal of gastroenterology and hepatology
  159. A Web-Based Prediction Model for Estimating the Probability of Post-hepatectomy Major Complications in Patients with Hepatocellular Carcinoma: A Multicenter Study from a Hepatitis B Virus-Endemic Area.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  160. Screening of Hepatocellular Carcinoma Patients with High Risk of Early Recurrence After Radical Hepatectomy Using a Nomogram Model Based on the γ-Glutamyl Transpeptidase-to-Albumin Ratio.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractRCT
  161. Acute-Phase Serum Amyloid A May Predict Microvascular Invasion and Early Tumor Recurrence in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Liver Resection.2022Journal of investigative surgery : the official journal of the Academy of Surgical Research
  162. A Double Suspension Technique for Laparoscopic Isolated Caudate Lobectomy.2022Journal of laparoendoscopic & advanced surgical techniques. Part A
  163. Extracellular microparticles derived from hepatic progenitor cells deliver a death signal to hepatoma-initiating cells.2022Journal of nanobiotechnologyFree full text
  164. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study.2022Liver international : official journal of the International Association for the Study of the Liver
  165. miR-2392 functions as tumour suppressor and inhibits malignant progression of hepatocellular carcinoma via directly targeting JAG2.2022Liver international : official journal of the International Association for the Study of the Liver
  166. Metabolomics-based classification reveals subtypes of hepatocellular carcinoma.2022Molecular carcinogenesis
  167. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevityFree full text
  168. The LINC00261/MiR105-5p/SELL axis is involved in dysfunction of B cell and is associated with overall survival in hepatocellular carcinoma.2022PeerJFree full text
  169. Risk factors and long-term prognosis of beyond-Milan recurrence after hepatectomy for BCLC stage 0/A hepatocellular carcinoma: A large-scale multicenter study.2022Surgery
  170. Sparse logistic regression revealed the associations between HBV PreS quasispecies and hepatocellular carcinoma.2022Virology journalFree full text
  171. NET1 promotes HCC growth and metastasis in vitro and in vivo via activating the Akt signaling pathway.2021AgingFree full text
  172. TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma.2021AgingFree full text
  173. Association between preoperative prealbumin level and postoperative mortality and morbidity after hepatic resection for hepatocellular carcinoma: A multicenter study from a HBV-endemic area.2021American journal of surgery
  174. Influence of postoperative adjuvant transarterial chemoembolization on the prognosis of early-stage intrahepatic cholangiocarcinoma: a single center study.2021Annals of palliative medicine
  175. Preoperative Estimated Risk of Microvascular Invasion is Associated with Prognostic Differences Following Liver Resection Versus Radiofrequency Ablation for Early Hepatitis B Virus-Related Hepatocellular Carcinoma.2021Annals of surgical oncology
  176. miR-93 regulates liver tumor initiating cells expansion and predicts chemotherapeutic response of patients.2021Archives of biochemistry and biophysics
  177. Stabilization of snail maintains the sorafenib resistance of hepatocellular carcinoma cells.2021Archives of biochemistry and biophysics
  178. Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis.2021BioengineeredFree full text
  179. Clinical utility of serum biomarkers for hepatocellular carcinoma.2021Biomarkers in medicine
  180. Oncostatin M promotes hepatic progenitor cell activation and hepatocarcinogenesis via macrophage-derived tumor necrosis factor-α.2021Cancer letters
  181. The difference in prolonged continuous and intermittent Pringle maneuver during complex hepatectomy for hepatocellular carcinoma patients with chronic liver disease: A retrospective cohort study.2021Cancer medicineFree full text
  182. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis.2021Cancer medicineFree full text
  183. RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding.2021Cell death & diseaseFree full text
  184. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients.2021Cell researchFree full text
  185. Incidence And Risk Factors Of Contrast Nephropathy After Tace In Patients With Liver Cancer And Chronic Kidney Disease.2021Clinical and investigative medicine. Medecine clinique et experimentale
  186. 4-phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR-α.2021Clinical and translational medicineFree full text
  187. The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients.2021Clinical cancer research : an official journal of the American Association for Cancer Research
  188. A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma.2021Clinics and research in hepatology and gastroenterology
  189. "Shared Decision Making Assistant": A Smartphone Application to Meet the Decision-Making Needs of Patients With Primary Liver Cancer.2021Computers, informatics, nursing : CIN
  190. Tumor cells derived-extracellular vesicles transfer miR-3129 to promote hepatocellular carcinoma metastasis by targeting TXNIP.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  191. Serum N-glycan fingerprint helps to discriminate intrahepatic cholangiocarcinoma from hepatocellular carcinoma.2021Electrophoresis
  192. TRIM56 suppresses the malignant development of hepatocellular carcinoma via targeting RBM24 and inactivating the Wnt signaling.2021European review for medical and pharmacological sciences
  193. The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing.2021Frontiers in immunologyFree full text
  194. The CD68+ macrophages to CD8+ T-cell ratio is associated with clinical outcomes in hepatitis B virus (HBV)-related hepatocellular carcinoma.2021HPB : the official journal of the International Hepato Pancreato Biliary Association
  195. Postoperative adjuvant transcatheter arterial chemoembolization improves the prognosis of patients with huge hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  196. ATP-citrate lyase regulates stemness and metastasis in hepatocellular carcinoma via the Wnt/β-catenin signaling pathway.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  197. Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis.2021Hepatology (Baltimore, Md.)
  198. HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3.2021Hepatology (Baltimore, Md.)
  199. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.2021Hepatology internationalFree full text
  200. Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China.2021Hepatology international
  201. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.2021Hepatology international
  202. N-glycan fingerprint predicts alpha-fetoprotein negative hepatocellular carcinoma: A large-scale multicenter study.2021International journal of cancer
  203. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.2021Journal of clinical laboratory analysisFree full text
  204. Thrombus-First Surgery for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  205. The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma.2021Journal of nanobiotechnologyFree full text
  206. Loss of STAT5A promotes glucose metabolism and tumor growth through miRNA-23a-AKT signaling in hepatocellular carcinoma.2021Molecular oncologyFree full text
  207. miR-369-3p serves as prognostic factor and regulates cancer progression of hepatocellular carcinoma.2021Personalized medicine
  208. Effect of PI3K/AKT/mTOR Signaling Pathway on Regulating and Controlling the Anti-Invasion and Metastasis of Hepatoma Cells by Bufalin.2021Recent patents on anti-cancer drug discovery
  209. Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway.2021Scientific reportsFree full text
  210. An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity.2021Signal transduction and targeted therapyFree full text
  211. SOX9-transactived long non-coding RNA NEAT1 promotes the self-renewal of liver cancer stem cells through PKA/Hippo signaling.2021Signal transduction and targeted therapyFree full text
  212. Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: A multicenter propensity score matching analysis.2021Surgery
  213. Using Quasispecies Patterns of Hepatitis B Virus to Predict Hepatocellular Carcinoma With Deep Sequencing and Machine Learning.2021The Journal of infectious diseases
  214. Extracellular-vesicles delivered tumor-specific sequential nanocatalysts can be used for MRI-informed nanocatalytic Therapy of hepatocellular carcinoma.2021TheranosticsFree full text
Chinese-language papers (not in the count)3
  1. [Systemic therapeutic strategies for hepatocellular carcinoma: current status and prospects].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Drug research and development and unmet needs for advanced-stage hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Combined hepatocellular-cholangiocarcinoma containing both large and small duct type cholangiocarcinoma: report of a case].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status73
  1. A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver CancerNot yet recruitingNCT07337031Lead sponsorN/AStart 2026-01
  2. Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver CancerNot yet recruitingNCT07363356Lead sponsorPhase 2Start 2026-01
  3. The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLDRecruitingNCT07285850Lead sponsorPhase 2/Phase 3Start 2025-10
  4. A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT06902389Lead sponsorPhase 1/Phase 2Start 2025-07
  5. Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular CarcinomaStatus unknownNCT05925413Lead sponsorPhase 2Start 2023-04
  6. Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular CarcinomaCompletedNCT05540925Lead sponsorStart 2022-01
  7. Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular CarcinomaStatus unknownNCT04386772Lead sponsorN/AStart 2020-05
  8. Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular CarcinomaStatus unknownNCT04523467Lead sponsorN/AStart 2020-12
  9. A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor CellsStatus unknownNCT04521491Lead sponsorN/AStart 2020-12
  10. Prospective Surveillance for Very Early Hepatocellular CarcinomaStatus unknownNCT03588442Lead sponsorStart 2018-07
  11. Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Recurrence in Hepatocellular Carcinoma PatientsStatus unknownNCT02523053Lead sponsorN/AStart 2016-04
  12. Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCCCompletedNCT03047603Lead sponsorStart 2016-05
  13. Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVICompletedNCT04891874Lead sponsorN/AStart 2015-08
  14. The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular CarcinomaStatus unknownNCT02525965Lead sponsorN/AStart 2015-08
  15. Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring SystemStatus unknownNCT02525952Lead sponsorN/AStart 2015-10
  16. Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular CarcinomaStatus unknownNCT02586285Lead sponsorPhase 1Start 2015-06
  17. Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular CarcinomaStatus unknownNCT02150317Lead sponsorN/AStart 2014-01
  18. Postoperative Adjuvant TACE Treatment in CK18 Positive PatientsCompletedNCT02724345Lead sponsorStart 2013-01
  19. Preoperative Pain Control in Liver Surgery PatientsCompletedNCT01923948Lead sponsorN/AStart 2013-05
  20. The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related GeneCompletedNCT01786980Lead sponsorStart 2012-10
  21. Relationship Between Circulating Tumor Stem Cells and the Clinical PathologyCompletedNCT02727673Lead sponsorStart 2012-12
  22. Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)CompletedNCT01643447Lead sponsorN/AStart 2012-05
  23. Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular CarcinomaCompletedNCT02724436Lead sponsorN/AStart 2012-12
  24. Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP ConversionCompletedNCT02728219Lead sponsorN/AStart 2012-05
  25. Targeted Internal Radiation Therapy in Advanced HCC Patients.CompletedNCT02724267Lead sponsorN/AStart 2012-11
  26. Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1CompletedNCT02724358Lead sponsorN/AStart 2012-12
  27. Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor ThrombusCompletedNCT02724475Lead sponsorN/AStart 2012-12
  28. Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCCCompletedNCT02724332Lead sponsorPhase 1Start 2012-11
  29. Standard Treatments of Very-early Stage Hepatocellular CarcinomaCompletedNCT02728193Lead sponsorN/AStart 2012-12
  30. Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular CarcinomaStatus unknownNCT01860222Lead sponsorN/AStart 2011-01
  31. Total Hemihepatic Vascular Exclusion in Hepatectomy in Hepatocellular Carcinoma TreatmentCompletedNCT00827047Lead sponsorN/AStart 2009-01
  32. Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in HepatectomyCompletedNCT00820339Lead sponsorPhase 2/Phase 3Start 2009-01
  33. A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver ResectionCompletedNCT00820053Lead sponsorPhase 2Start 2009-01
  34. Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCCCompletedNCT00834158Lead sponsorN/AStart 2009-01
  35. Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver CancerCompletedNCT00822562Lead sponsorN/AStart 2009-01
  36. Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular CarcinomaCompletedNCT00820157Lead sponsorN/AStart 2008-11
  37. A Trial of Licartin for Preventing Tumor Recurrence After Liver ResectionCompletedNCT00819650Lead sponsorPhase 2Start 2008-12
  38. Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma ResectionCompletedNCT00825669Lead sponsorN/AStart 2008-12
  39. A Trial of Complete Versus Selective HepaticVascular Clamping in HepatectomyCompletedNCT00851968Lead sponsorN/AStart 2008-12
  40. Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood VesselsCompletedNCT00814242Lead sponsorPhase 2/Phase 3Start 2008-12
  41. Intraoperative Chemotherapy Against Hepatocellular Carcinoma RecurrenceCompletedNCT00817895Lead sponsorN/AStart 2008-12
  42. Efficacy and Significance of Antiviral Therapy for Unresectable Hepatitis B Virus-related Primary Liver CancerCompletedNCT00824707Lead sponsorN/AStart 2008-12
  43. A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular CarcinomaCompletedNCT00825474Lead sponsorN/AStart 2008-08
  44. The Role of Low Molecular Weight Heparins in Hepatocellular CarcinomaCompletedNCT00827554Lead sponsorPhase 2/Phase 3Start 2008-12
  45. Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing PerfusionCompletedNCT00826384Lead sponsorPhase 1/Phase 2Start 2008-10
  46. Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma PatientsCompletedNCT00849264Lead sponsorPhase 2Start 2008-12
  47. Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPHStatus unknownNCT02587884Lead sponsorPhase 1
  48. HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)Status unknownNCT06210334Lead (inferred)Phase 2Start 2024-03
  49. Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma OrganoidActive, not recruitingNCT06699524Lead (inferred)Start 2022-09
  50. Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular CarcinomaStatus unknownNCT02632188Lead (inferred)Phase 1/Phase 2Start 2015-09
  51. Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT02638857Lead (inferred)Phase 1/Phase 2Start 2015-09
  52. Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT02632006Lead (inferred)Phase 1/Phase 2Start 2015-09
  53. Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After HepatectomyStatus unknownNCT02399033Lead (inferred)Phase 4Start 2014-06
  54. A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular CarcinomaStatus unknownNCT02253511Lead (inferred)Phase 4Start 2014-07
  55. S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT01533324Lead (inferred)Phase 2Start 2011-11
  56. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  57. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08
  58. Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in ChinaEnrolling by invitationNCT06712017Study siteStart 2024-08
  59. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  60. Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCCWithdrawnNCT06361758Study sitePhase 2Start 2024-05
  61. A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).TerminatedNCT05975645Study sitePhase 1Start 2023-08
  62. Auxiliary Diagnosis of Liver Nodules Using cfDNA Whole-genome SignaturesStatus unknownNCT05393102Study siteStart 2022-05
  63. Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular CarcinomaStatus unknownNCT05626985Study siteStart 2022-10
  64. Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaStatus unknownNCT05389527Study sitePhase 2Start 2022-09
  65. Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver CancerWithdrawnNCT05292443Study siteStart 2021-12
  66. A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILsStatus unknownNCT04538313Study sitePhase 1/Phase 2Start 2020-08
  67. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  68. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)CompletedNCT04000737Study sitePhase 2Start 2020-01
  69. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  70. A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein InvasionStatus unknownNCT03971201Study sitePhase 2Start 2019-09
  71. Efficacy Study of TACE to Treat Hepatocellular Carcinoma After OperationStatus unknownNCT02631499Study sitePhase 4Start 2015-12
  72. The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular CarcinomaStatus unknownNCT01055743Study sitePhase 2Start 2009-08
  73. Urea Cream Treatment Sorafenib-Associated HSFR in HCCCompletedNCT01934829Study sitePhase 2Start 2009-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 6 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.06%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 222025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseSurgeryImaging & AI
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 112025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Study sitePhase 3Start 2009-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Shanghai for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

海军军医大学第三附属医院(东方肝胆外科医院)

Eastern Hepatobiliary Surgery Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Eastern Hepatobiliary Surgery Hospital; Shanghai Eastern Hepatobiliary Surgery Hospital; Eastern Hepatobiliary Surgery Institute; Third Affiliated Hospital of Second Military Medical University; Third Affiliated Hospital of Naval Medical University; Eastern Hepatobiliary Surgery Hospital/Institute; Eastern Hepatobiliary Surgery Institute/Hospital; Eastern Hepatobiliary Hospital

Suggest a correctionDownload the data